Navigation Links
AtheroNova Completes Successful Pre-IND Meeting with FDA on AHRO-001
Date:10/26/2011

t sectors potentially served by AHRO-001 include: Cardiovascular Disease, Stroke, Peripheral Artery Disease, Dementia and Alzheimer's and Erectile Dysfunction, all of which have been linked to atherosclerosis.

About AtheroNova

AtheroNova Inc., through its wholly-owned subsidiary, AtheroNova Operations, Inc., is an early stage biotech company focused on discovery, research, development and licensing of novel compounds to reduce or regress atherosclerotic plaque deposits. The Company's focus on compounds to reduce or eliminate atherosclerotic plaque deposits addresses the most lucrative segments of the multi-billion dollar prescription drug market: cardiovascular disease and stroke prevention. www.AtheroNova.com.

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the Company's pipeline, milestones, future filings and trials, markets, mechanisms of action, licensing agreements and equity investment as well as the development of applications for AtheroNova's technology. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and
'/>"/>

SOURCE AtheroNova Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013  Lakeland Industries, Inc. (NASDAQ: LAKE ... industry, healthcare and to first responders on the federal, ... for the fiscal 2013 fourth quarter and year ended ... stock market close and will conduct a conference call ... (Logo: http://photos.prnewswire.com/prnh/20120611/NY21959LOGO ) The ...
(Date:5/17/2013)... DIEGO and CAMBRIDGE, Mass., May 17, 2013 /PRNewswire/ ... that a purchaser of Aveo Pharmaceutical, Inc. (NASDAQGS: AVEO) ... Court for the District of Massachusetts ... its officers violated the Securities Exchange Act of 1934 ... 1, 2013 (the "Class Period"). (Logo: ...
(Date:5/17/2013)... PHILADELPHIA , May 17, 2013 ... disorders; health economics and outcomes research also   to ... SHP, NASDAQ: SHPG ), the global specialty ... in 7 poster presentations at the American Psychiatric Association ... , May 18-22. The data being presented represent ...
Breaking Medicine Technology:Lakeland Industries to Report Fiscal Fourth Quarter and Year End Financial Results and Conduct Conference Call 2Aveo Pharmaceuticals, Inc. Sued by Investor 2Aveo Pharmaceuticals, Inc. Sued by Investor 3Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 2Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 3Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 4Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 5Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 6Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 7Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 8Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 9Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 10
... 3, 2012 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP ... biotechnology research and development outsourcing company, today announced that it ... ended March 31, 2012 on May 17, 2012. Management will ... New York Time on May 17, 2012 (8:00PM Beijing Time ...
... Pharmaceuticals, Inc. (NASDAQ: OPTR ) today announced ... America Merrill Lynch 2012 Health Care Conference on Thursday, May 17 ... (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO ) A ... on the Investors page of the Company,s website at ...
Cached Medicine Technology:ShangPharma to Report First Quarter 2012 Financial Results on May 17, 2012 2
(Date:5/19/2013)... 2013 Actos lawsuit claims ... underway in U.S. District Court, Western District of Louisiana. ... 3rd, the Court has modified the litigation’s Bellwether Nomination ... rather than four. The next Status Conference in the ... (In re: Actos Product Liability Litigation, MDL No. 2299) ...
(Date:5/19/2013)... Grinding your teeth at night can ... annoying your spouse. At the same time, according to ... and Teeth Grinding Could Be a Sign of Sleep ... be hard to prevent. Apparently, Obstructive Sleep Disorder (OSD) ... its symptoms is a habit of teeth grinding along ...
(Date:5/19/2013)... 2013 These molecular diagnostics market ... Spain, Japan, Italy, Germany and France:, ... laboratory practice, as well as key economic, regulatory, ... impact during the next five years. , ... technologies, test formats, detection methodologies, trends in testing ...
(Date:5/19/2013)... York (PRWEB) May 19, 2013 The ... Case Management Conference was recently convened for hundreds of ... multidistrict litigation now underway in U.S. District Court, Southern ... the Court’s website on May 14th, the Conference addressed ... was also reported during the Conference that Defendants submitted ...
(Date:5/19/2013)... Keith Chertok now provides gum disease patients with a new ... chance of a healthier smile. Laser gum surgery ... removes diseased gum tissue in patients, but it also stimulates ... implants. , LANAP uses a laser to successfully treat ... the healthy tissue as well as encourage new bone growth. ...
Breaking Medicine News(10 mins):Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Dr. Kanani, Woodland Hills Dentist: Dangers of Tooth Damage and Obstructive Sleep Disorder 2Health News:Dr. Kanani, Woodland Hills Dentist: Dangers of Tooth Damage and Obstructive Sleep Disorder 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 2Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 4Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 2Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 3Health News:Berkeley, CA Periodontist, Dr. Keith Chertok Now Treats Gum Disease Patients With Laser Gum Surgery Prior to Placing Dental Implants 2
... Medical, Inc., a,privately held medical device company and ... announce the addition of two officers to,their management ... Finance and Chief Financial Officer. Tara Zerby joins ... "We are very excited to have Malcolm ...
... (NASDAQ: QLTI;,TSX: QLT) today announced that following a months-long business ... several,new initiatives designed to enhance shareholder value., These ... USA, Inc. whose primary assets include the Eligard(R) ... dermatology product for the treatment ...
... JOLLA, Calif., Jan. 16 Immunosyn,Corporation (OTC Bulletin ... of an Equity Research Profile on the company ... research company, nor the,associated press release announced earlier ... only authorized public and investor,relations firm retained by ...
... 17 One of Australia,s largest,pharmacy groups, Chemmart, has ... competitive threat posed by discount chains., The system ... month of,operation, participating pharmacies signed up more than 30,000 ... Results Group, has now been,rolled out to more than ...
... interventions were implemented in poor countries, cases of stunting among ... by up to a quarter, according to new research being ... of Hygiene & Tropical Medicine, is one of the authors ... Maternal and Child Undernutrition Series, which is being launched this ...
... MOUND, Texas, Jan. 16 American,HealthChoice, Inc. (Pink Sheets: ... and Tennessee, today, in an update for Company,shareholders, said ... 2007,totaled $243,000., "It was a year of positioning, ... CEO. "I am updating our shareholders on these,achievements as ...
Cached Medicine News:Health News:Cardiva Medical, Inc. Appoints Two New Officers: Malcolm Farnsworth as Vice President of Finance and Chief Financial Officer and Tara Zerby as Vice President of Business Development and Marketing 2Health News:QLT Inc. announces initial steps in strategic restructuring 2Health News:QLT Inc. announces initial steps in strategic restructuring 3Health News:QLT Inc. announces initial steps in strategic restructuring 4Health News:Equity Research Firm Issued Unauthorized Report and Press Release on Immunosyn Corporation Today 2Health News:Chemmart(R) Sees Instant Results From Launch of New Rewards Program 2Health News:One third of stunting and a quarter of deaths among under 3s in poor countries could be prevented 2Health News:American HealthChoice CEO Dr. J.W. Stucki Provides Company Update 2Health News:American HealthChoice CEO Dr. J.W. Stucki Provides Company Update 3
... Used retrograde to ... establish a Peel-Away ureteral ... The temporary protective Peel-Away ... away as the ureteroscope ...
The removable inflation/injection adapter allows the cystoscope to be removed after the catheter is in place. Supplied sterile in peel-open packages. Intended for one-time use....
Radiopaque markers are placed at the proximal and distal ends of the balloon. A special pin vise handle is included to stabilize the wire guide during introduction. Supplied sterile in peel-open pack...
Used during the performance of balloon dilation procedures to inflate and deflate the balloon and measure the pressure within the balloon during the procedure. Supplied sterile in peel-open packages....
Medicine Products: